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ABSTRACT 
 
Characterization of Adherence Properties of the VWFA-domain  
Containing Proteins of the Causative Agent of Lyme Disease  
(May 2012) 
 
Elaine Wood 
Department of Biology 
Texas A&M University 
 
Research Advisor: Dr. Maria Esteve-Gassent 
Department of Veterinary Pathobiology 
 
The bacterial spirochete Borrelia burgdorferi, the causative agent of Lyme disease (LD) 
encodes for the von Willebrand Factor A (VWFA) domain proteins BB0172 and BB0173. 
VWFA domains are commonly known for adhering to extracellular matrix components 
(ECM), glycoproteins and metaloproteases. In silico analysis shows both of these proteins 
as membrane proteins. Moreover, in vitro analysis shows that both proteins have a 
transmembrane domain that anchors the protein to the cellular membrane with the VWFA 
domain available outside of the cell. The use of binding assays will help determine whether 
BB0172 and BB0173 play a role in the adhesion of Borrelia burgdorferi to ECM 
components, such as, Collagen I and IV, Laminin, plasma and cellular Fibronectin, among 
others, together with the use of commercially available purified integrins (αvβ3, α5β1 and 
α3β1). Both rBB0172T and rBB0173T showed to be difficult to purified under native 
conditions, and therefore we developed a new purification protocol in which denatured 
proteins were purified in a buffer containing 8M Urea, and latter on re-natured by 
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elimination of the Urea using dialysis and concentration methods. Moreover, both proteins 
showed binding to the ECM human plasma fibronectin under the presence of the metals 
Ca2+, Mg2+ and Mn2+. No binding was observed to any of the other ECMs (collagen I and 
IV, laminin, decorin, aggrecan, vitronectin, fibrinogen and elastin) nor the integrins tested. 
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NOMENCLATURE 
 
LD Lyme Disease 
Bb Borrelia burgdorferi 
VWF Von Willebrand Factor  
EM Erythema migrans 
ECM Extracellular matrix  
Fn Fibronectin 
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This thesis follows the style of Infection and Immunity.  
 
CHAPTER I 
INTRODUCTION 
 
Lyme disease is the most common tick-borne infectious disease in the US with a total of 
22,572 confirmed human cases reported to the CDC in 2010. Lyme disease (LD) is 
caused by the bacterial spirochetes Borrelia burgdorferi senso lato and is transmitted by 
the tick vector Ixodes scapularis in northeastern North American, Ixodes pacificus in 
mid-western North America, Ixodes ricinus and Ixodes persulcatus in Europe and Ixodes 
ovatus in Asia (2, 3, 17). LD, or also called Lyme borreliosis, is a multisystemic disease 
characterized by the presence of up to three disease stages when left untreated. 
 
The first stage of LD features the most common symptom, erythema migrans (EM). EM 
shows 1 to 3 weeks after the initial tick bite and starts as a erythematous papule that 
extends circularly around the site of infection up to 3 cm a day (3). EM normally occurs 
at the source of the tick bite mostly on the back, lower extremities or axilla. Overall, 
only 60-70% of cases have EM with central clearing, but EM without central clearing 
may occur as well (3). EM tends to occur more often in the USA than Europe (17). Other 
symptoms that may take place during the first stage of LD are fatigue, fever, headache, 
pain localized to the tick bite or regional lymphadenopathy (3, 17). The second stage of 
LD exhibits signs of dissemination with multiple EM sites and complications with 
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neurologic and cardiac systems (3, 17). The neurological symptoms can lead to 
meningitis and cranial neuritis, more common in children. The common cardiac 
symptom is a first-degree atrioventricular block (3, 17). The process of dissemination 
may begin as early as the first week of infection to months after the initial tick bite (3, 
17). During the second stage of LD also begins the manifestation of arthritis; up to one 
third of patients may show symptoms of joint pain (3, 6, 17, 18). The third stage of LD 
comprises neurological involvement, further cardiac problems, and chronic arthritis (6, 
18). Neurological involvement starts with lymphocytic meningitis, cranial neuritis and 
radiculoneuritis in up to 15% of LD patients (3, 17). Neurological symptoms begin 
during early dissemination, but during the third stage of LD neurological symptoms may 
lead to more severe neurological complications such as polyneuropathy and cranial 
neuropathy .  
 
 
 
 
FIG 1. Infectious cycle of Borrelia burgdorferi.  
B. burgdorferi is transmitted to competent host by the bite of infected Ixodes ticks. Upon 
hatching larvae are not infected with Bb, and they use to acquire the infectious agent after 
acquiring their blood meal on an infected mammal. A red cross indicates a less preferred 
reservoir host. (Adapted from “Lyme borreliosis” Stanek G). 
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The Ixodes tick life cycle plays an important role in Bb infection. The Ixodes tick life 
cycle consists of three stages. As observed in figure 1, the first stage comprises eggs 
hatching and transitioning into larvae in the spring of their first year (3). The second 
stage begins during summer of year one, when the larvae will mold into nymphs after 
their first blood meal (3). The nymphs, the most aggressive stage, will then take their 
blood meal, and transform into adults during the third stage (30). This occurs during the 
summer of year 2. When the tick feeds on an infected host it then becomes infectious. 
Transition of Bb from the adult tick mother to her eggs is extremely rare (30). Common 
mammalian reservoirs include the cottontail rabbit, the dusky-footed wood mouse, the 
cotton rat, cotton mouse, and white-footed mouse for the larvae and nymph stages. 
Larger mammalian reservoirs such as deer and horses are common hosts for the nymph 
and adult stages.  
 
Transmission of the Bb senso lato takes place while feeding on the infected host. Bb 
remains attached in the tick’s midgut epithelium. Once infected the tick will remain so, 
but rarely transmit the bacteria to its offspring, transmission of Borrelia to a host 
manifests while the tick is feeding (28). The differences in temperature and pH from the 
tick to host during feeding trigger the bacteria in the tick midgut allowing it to migrate 
from the tick midgut to the salivary glands and into the mammalian host (28, 29). This 
process is important to the two borrelia proteins BB0172 and BB0173 that will be 
studied in this thesis, as they have been shown in vitro to appear after shifting in vitro 
growth conditions from those mimicking the un-fed tick vector to those mimicking the 
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mammalian host (Dr. Esteve-Gassent, personal communication, manuscript in 
preparation).  
 
BB0172 and BB0173 are two von Willebrand Factor A (VWFA) domain carrying 
proteins in Borrelia burgdorferi. Both proteins are membrane proteins by in silico 
analysis using TMMHM 2.0. In vitro studies performed in our laboratory showed that 
the transmembrane domains of each protein anchor these proteins to the membrane with 
the VWFA domain expanding on the outside of the cell. The topology of BB0172 
considering the in silico study using TMMHM 2.0 and SignalIP4.0 is shown in Figure 2.  
 
VWFA domain containing proteins performs a central role in the adherence of platelets 
in areas of vascular damage (39). VWF, a multimeric plasma glycoprotein, play this role 
by binding to extracellular matrix components (ECM), glycoproteins, and to 
metalloproteases (15, 23, 32, 39). The absence of VWF proteins, in humans, can result in 
severe bleeding disorders, or von Willebrand disease due to the lack of coagulation by 
the removal of the blood clotting factor VIII (27). This disease is the most common 
inherited bleeding disorder in humans. 
 
VWF proteins have been recognized in other bacterial infections such as Helicobacter 
pylori and Staphylococcus aureus (4, 5, 8). The VWFA-domain containing proteins in 
each of these pathogens help bind to ECM elements as well as adhesion to platelets and 
endothelial cells. Therefore, this factor can have an important role in the dissemination 
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of the infection into the mammalian host. The VWFbp protein in Helicobacter pylori is 
known to bind to the Ib glycoprotein on platelets (8). Staphylococcus aureus VWFbp 
domain was able to coagulate the plasma of human’s and porcine. Many other VWF 
binding proteins have been identified and are know to bind to ECM components such as 
collagen (28, 29, 39). In order to test the role of VWFA domain as an adhesion molecule 
in the proteins BB0172 and BB0173, a series of binding tests to various ECM 
components, including Fibronectin from humans and plasma, Collagen I and IV and 
Laminin as well as binding assays to commercially available integrins (αvβ3, α5β1 and 
α3β1) and platelets will be conducted (9, 11-13). 
 
 
 
  
FIG 2. BB0172 Topology. (A) Chromosome region where bb0172 and bb0173 are encoded. (B) 
Structural components of BB0172: the signal peptide comprises amino acids 1-39, with cleavage site in 
between amino acid 39-40 (QRA-VE), tranmembrane domains extend from amino acid 16-38 and 253-
284. A glycosylation site is located in amino acid 198 to 200. The VWFA domain extends from amino 
acids 45 to 250. 
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CHAPTER II 
 
METHODS 
 
Recombinant protein expression and purification  
Induction and growth conditions 
Previously in our laboratory Dr. Esteve-Gassent cloned truncated versions of the Bb 
proteins BB0172 (bb0172) and BB0173 (bb0173) without the first 50 or 90 amino acids 
respectively (so as to remove the signal peptide), P66 (bb0603) and BBK32 (bbk32) 
(unpublished information) in the expression vector pET23a (Novagen) and in the 
expression E. coli host Rosetta® and Rosetta-gami® strains (Novagen). Reference Table 
1 for the list of plasmid constructs and bacterial strains.  To express rBB0172T, 
rBB0173T , rBBK32 and rP66,  overnight cultures were started in 10 mL of LB broth 
media containing their respective antibiotic and incubated overnight at 37ºC with 
continuous shaking. The following day the overnight culture was added 1:100 dilution to 
1 L of fresh LB broth media with their respective antibiotics and incubated at 37ºC under 
continuous shaking until the Optical Density (OD) at 600nm reached a value of between 
0.5 and 0.8. Proteins were induced by the addition of Isopropil β–D-
thiogalactopyranoside (IPTG) to the grown cultures at a final concentration of 1mM and 
incubated at 37ºC for 2 hours. After the 2 hours incubation, cells were harvested by 
centrifugation at 4000rpm for 20 minutes and 4ºC. The pellet was then stored at -80ºC 
for further use. 
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TABLE 1: Plasmids, bacterial strains and antibiotics used in the expression of the 
different borrelial proteins. 
 
Protein Stain Antibiotic Concentration (µg/ml) 
pET23a(bb0172)50-290 Rosetta-gami ® Ampicillin  
Chloramphenicol 
Kanamycin 
Tetracycline 
100 
20 
34 
10 
    
pET23a(bb0173)90-333 Rosetta ® Ampicillin 
Chloramphenicol  
100 
20 
    
pET23a(bbk32) Rosetta® Ampicillin  
Chloramphenicol  
100 
20 
    
pET23a(p66) Rosetta® Ampicillin  
Chloramphenicol  
100 
20 
 
 
 
Purification of recombinant proteins 
The purification of each recombinant protein was achieved under denaturing conditions. 
The buffers for this process included a lysate buffer, a wash buffer and an elution buffer 
as per His60 Ni SuperflowTM Resin and Gravity Columns Users Manual (Clontech). The 
lysate buffer consisted of 50 mM NaH2PO4, 8 M urea, 300 mM NaCl, and 20 mM 
imidazole with a pH of 7.4. The wash buffer includes 50 mM NaH2PO4, 8 M urea, 300 
mM NaCl, and 40 mM imidazole with a pH of 7.4. The elution buffer contains 50 mM 
NaH2PO4, 8 M urea, 300 mM NaCl, and 300 mM imidazole with a pH of 7.4. All buffers 
were autoclaved and stored at 4ºC. To purify the proteins, harvested cells were thawed 
on ice and re-suspended in 10 mL of the lysate buffer plus a protease inhibitor. Cells 
were lyzed by French Press (FP) (Thermo Scientific), running the mixture through the 
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machine 2-3 times to completely lysate the cells. The lysate was cleared by 
centrifugation at 4000 rpm for 20 minutes. The supernatant of this centrifugation is then 
added to 5 mL of previously equilibrated nickel His60 Ni Superflow Resin (Clontech) 
and incubated at 4ºC overnight with gentle shaking. After binding the recombinant 
proteins to the beads through the histidine tag, the Ni bead mixture was  sedimented at 
500 rpms for 5 minutes. Post adsorption supernatant (PASN) was stored at -80ºC until 
purification of each recombinant protein was confirmed. Ni beads were washed with 
10ml of  the washing buffer 3 times by sedimenting them at 500rpm for 5 minutes. 
Beads were re-suspended in 10 mL of the wash buffer and loaded in chromatography 
columns connected to a peristaltic pump.  Each recombinant protein was eluted by 
adding10 mL of the elution buffer to the gravity column and collecting 0.5 mL to 1 mL 
fractions. A total of 20 to 25ml of the elution buffer was needed per extraction to 
completely elute each one of the recombinant proteins purified in this study. Fifty µL of 
each fraction as well as the washing fractions, the PASN and the FP lysates were mixed 
with 50 µL of 2x Final Sample Buffer (2x FSB, SDS-PAGE loading buffer), boiled for 5 
minutes and stored at -20ºC until use. All the elution fractions, washes and PASN were 
stored at -80ºC until use.  
 
Protein clean up and concentration 
For each recombinant protein, elution fractions, PASN and washes were separated in a 
12% SDS-PAGE gel, to determine the elution fractions containing the majority of the 
protein. . Once the appropriate fractions were determined they were placed in a dialysis 
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Cassettes (Slide-A-Lyzer, Thermo Scientific) and stirred for 2 hours at room temperature 
in a dialysis buffer (50 mM NaH2PO4 and 300 mM NaCl). After 2hrs, the old dialysis 
buffer was replaced with fresh buffer and incubated stirring for 1 more hour. Once 
dialysis was finished the clean protein fraction was recuperated and spun using 
AmicoUltra filtration systems to concentrate the protein before storing them at -80ºC.  
The protein concentration in each one of the clean protein fraction’s was determined 
using the BCA Protein Assay Kit (Thermo Scientific) following manufacturer’s 
recommendations. Briefly, serial dilutions of a known protein standard provided in the 
kit (BSA, 2mg/ml) were done ranging from 0 to 250µg/ml). Each recombinant protein 
was diluted 1:5 and 1:10. Twenty-five µl of each one of the samples or the standards 
were added in triplicates to 96-well plates (Corning). After adding the working reagent 
(provided by the kit) samples were incubated at 37ºC for 30 minutes. Protein 
concentration was measured using the BGI OMEGA plate reader and adjusted in the 
downstream binding assays performed.  
 
Binding Assays 
Plates coated in extra cellular matrix components 
Pre-coated 96 well plates (BioCoat, BD) with Lamin, Collagen I, Collagen IV, and 
Fibronectin were used in this part of the study. The plates were blocked with blocking 
buffer (Phosphate Buffer Saline (PBS: 137mM sodium chloride, 2.7mM potassium 
chloride, 4.3mM sodium phosphate 1.4mM potassium phosphate, pH 7.4), 0.5% tween 
20, and 3% Bovine Serum Albumin (BSA)) for 2 hours at room temperature. The 
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binding of the purified proteins was done by adding 500 ng/well and 100 ng/well of each 
of the recombinant proteins (BB172T, BB0173T and BBK32) in PBS-T (PBS containing 
0.5% Tween 20) for 1 hour at room temperature. The plates were then washed with PBS-
T and incubated with a 1:1000 dilution of mouse anti-BB0172 or anti-BB0173 or 1:2000 
dilution of the anti-BBK32 for 1 hour at room temperature. The plates will then be 
washed and a secondary anti-mouse-HRP conjugated antibodies at a 1:3000 dilution will 
be added and incubated for 1 hour at room temperature. After a final wash the plates 
were developed using OPD tablets (Thermo Scientific) and the OD at 450 mm read in a 
BGI Omega plate reader. Wells with no recombinant protein were used as blanks. 
 
Plates coated with BB0172T, BB0173T and BBK32 
Plates were first coated with 500ng/well of each of the respective recombinant protein. 
After coating overnight at 4ºC plates were washed and blocked using the PBS-T with 3% 
BSA buffer for 2 hours at room temperature. Blocked plates were washed and incubated 
for 1 hour at room temperature with 500 ng/well of each of the ECM components 
specified in table 2 (1, 10). After washing, plates were incubated for 1hr at room 
temperature with the respective anti-ECM component for 1 hour at room temperature. 
The plates will then be washed and a secondary HRP conjugated antibody was applied 
for 1 hour at room temperature before being developed with the OPD tablets (Thermo 
scientific) as described above. Wells without ECM components were used as blanks. In 
addition we also ran this protocol using HBS buffer (25 mM HEPES, 150 mM NaCl, 1 
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mM MnCl2, 1 mM MgCl2, 0.25 mM CaCl2) containing Ca2+, Mg2+ and Mn2+ instead of 
the PBS. The same percent of BSA or Tween was used for blocking, washing and 
antibody and ECM component incubation (10).  
 
Integrin coated plates 
Plates were first coated with 500ng/well of each of the respective integrins specified in 
Table 3. After coating overnight at 4ºC plates were washed and blocked using the HBS-
T with 3% BSA buffer for 2 hours at room temperature. Blocked plates were washed and 
incubated for 1 hour at room temperature with 500 ng/well of each of the recombinant 
proteins (BB0172T, BB0173T and P66). After washing, plates were incubated for 1hr at 
room temperature with 1:1000 dilution of the mouse anti-BB0172 or anti-BB0173 or 
with 1:2000 dilution of the mouse anti-P66 specific antibody. The plates will then be 
washed and a secondary anti-mouse-HRP conjugated antibodies at a 1:3000 dilution will 
be added and incubated for 1 hour at room temperature. After a final wash the plates 
were developed using OPD tablets (Thermo Scientific) and the OD at 450 mm read in a 
BGI Omega plate reader. Wells without integrins were used as blanks. All samples were 
studied in triplicates. 
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TABLE 2: List of ECM components used in Binding Assays 
ECM component Purified protein Specific antibody 
Fibronectin 
(from human plasma) F0895-1mg F3648-0.2ml 
(in Rabbit) Fibronectin 
(from human fibroblast culture) F0556-100µl 
Fibrinogen 
(from human plasma) F3879-250mg 
F8512-2ml 
(in Goat) 
Decorin 
(from Bovine articular cartilage) D8428-0.5mg 
SAB2501273-100µg 
(in Goat) 
Aggrecan 
(from Bovine anticular cartilage) A-1960-1mg 
SAB4500662-100µg 
(in Rabbit) 
Vitronectin 
(human recombinant) SRP3186-250µg 
SAB2102690-50µg 
(in Rabbit) 
Elastin 
(from human aorta) E6777-2mg HPA018111-100µL 
Anti-Goat Peroxidase labeled  A5420-1ml 
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TABLE 3: List of integrins used in Binding Assays 
Integrin Catalog # Function 
α1β1 CC1012 
It is a receptor for laminin and collagen. It recognizes the 
proline-hydroxylated sequence G-F-P-G- E-R in collagen 
   
α3β1 CC1092 
It is a receptor for fibronectin, laminin, collagen, epiligrin, 
thrombospondin and CSPG4. Alpha- 3/beta-1 may mediate 
with LGALS3 the stimulation by CSPG4 of endothelial cells 
migration 
   
αVβ3 CC1018 
αV is a receptor for vitronectin, cytotactin, fibronectin, 
fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, 
osteomodulin, prothrombin, thrombospondin and von 
Willebrand factor. They recognize the sequence R-G-D in a 
wide array of ligands. 
   
αVβ5 CC1024 
αV is a receptor for vitronectin, cytotactin, fibronectin, 
fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, 
osteomodulin, prothrombin, thrombospondin and von 
Willebrand factor. They recognize the sequence R-G-D in a 
wide array of ligands 
   
α5β1 CC1052 
It is a receptor for fibronectin and fibrinogen. It recognizes the 
sequence R-G-D in its ligands 
   
GPIIbIIIa 528240 
Native, platelet membrane glycoprotein IIbIIIaA from human 
platelets. A platelet integrin that binds to fibrinogen via the 
recognition sequence Arg-Gly-Asp-Ser. Acts as a receptor for 
such adhesive ligands as fibrinogen, fibronectin and von 
Willebrand factor during platelet stimulation. Glycoproteins 
IIb and IIIa constitute the fibrinogen receptor and are required 
for platelet aggregation. Glycoprotein IIb consists of two 
disulfide-linked subunits, GPIIbα and GPIIbβ, whereas 
GPIIIα has only one polypeptide chain 
 
  
  14 
 
CHAPTER III 
RESULTS 
 
Recombinant protein purification and expression 
SDS-PAGE gel 
After growing the bacterial clone expressing each of the recombinant proteins as 
described above, we induced their expression for 2hrs at 37ºC. Once the induction was 
terminated, cells were disrupted by French Press in the cold to prevent any protein 
degradation. Recombinant proteins were purified utilizing their binding to Ni 
chromatography through the 6*His tag engineered in their C terminus end. Each one of 
the eluted fractions together with the induction lysate and the post-absorbion supernatant 
(resulting from the binding of the recombinant proteins to the Ni beads) were separated 
in a 12% separating SDS-PAGE gel (Figure 3). These gels were used to determine which 
fractions to use in the downstream assay. As observed in figure 3A and B, BB0172T and 
BB0173T expressed in very low amounts giving positive elution fraction 4-9 for 
BB0172T and fractions 5-10 for BB0173T. This result was expected since both proteins 
are membrane proteins and they tend to be toxic when expressed in E. coli. Thus, by 
eliminating the signal peptide and transmembrane domain in the N-terminus of these 
proteins during the cloning process (data not shown), we made them soluble and easy to 
purify in enough concentrations to carry out the downstream binding assays, as well as 
to generate specific antibodies for other applications. On the other hand, BBK32 was 
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induced in higher concentrations (figure 3C). For this recombinant protein elution 
fractions E2 though E12 and above had enough protein to do the whole proposed study.  
Selected fractions were then pooled for each recombinant protein and dialyzed to 
eliminate the Urea and imidazole used in the purification process. Samples were 
concentrated and stored at -80ºC for further use. 
 
 
 
(A)     (B) 
     
 
(C) 
 
FIG 3. Recombinant BB0172T (A) rBB0173T (B) and rBBK32 (C) purification. Fractions were 
separated by 12% SDS-PAGE gels and stained with Coomassie blue. MW is the molecular weight in 
kDa (Ez-Run, Thermo Fisher). The whole cell lysate, the post adsorption supernatant (PASN) and the 
wash 1 and 2 (W1 and W2) were loaded to determine whether the protein was expressed correctly and 
whether or not it was lost in the different purification steps. All the collected elution fractions were 
loaded to determine those containing the majority of the purified protein (E1 though E 23).  
  16 
 
 
 
FIG 4. Representative Standard curve of BCA Assay Kit.  
BCA assay 
After dialysis and filtration the purified proteins were quantified using the BCA Assay 
(Thermo Scientific). This kit uses a set of 6 standards ranging from 0 µg/mL to 250 
µg/mL. Replicates of 1:5 and 1:10 dilutions of each recombinant protein were compared 
to these standards to determine their concentration. rBB0172T and rBB0173T 
concentrations ranged from 25 µg/mL to 125 µg/mL, and rBBK32 concentrations 
averaged 625 µg/mL. A standard curve was used to establish the fitness of each 
concentration (figure 4). Fitness, r2, was measured to be above 0.99.  
 
 
 
 
  17 
 
 
Binding Assays 
Extra cellular matrix components binding assays 
Two different approaches were used in this study. In the first approach we used pre-
coated plates with different human ECM (Table 2, BD BioCoatTM). In those plates, both 
BB0172T and BB0173T showed very little to no binding to each of the ECM components 
tested, compared to the control BBK32 (figure 5). BBK32 showed high affinity for 
Fibronectin, Collagen I and IV and much lower binding to Laminin.  
 
 
 
 
 
 
Since BB0172 showed a little binding with Fibronectin, we decided to repeat the binding 
assay using human plasma and tissue fibronectin. Moreover, it has been previously 
 
 
FIG 5. ECM Binding Assay with pre-coated plates. ECM Binding Assay to pre-
coated plates with ECM components Collagen I, Collagen IV, Fibronectin, and 
Laminin (BD BioCoat) 
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reported that proteins such as BBK32 bind different to either one of them (14, 19, 22, 24, 
33-36). To test whether BB0172 and BB0173 had differential binding such as the one 
observed with BBK32, we coated 96-well plates with 500ng/well of each one of our 
recombinant proteins. After incubating with 500ng/well of the human plasma or tissue 
fibronecting plates were developed and OD450nm was read using a plate reader. As 
observed in Figure 6, the control rBBK32 showed high binding to the human plasma 
Fibronectin while it bound with lower intensity to tissue fibronectin, BB0173T showed 
no binding to either Fibronectin substrate. BB0172T shows very little binding to Human 
Fibronectin from tissue, but no binding to Human Fibronectin from plasma.  
 
 
 
 
 
 
 
 
FIG 6. ECM Binding Assay coated with recombinant proteins. ECM Binding 
Assay to plates coated with recombinant protein showing their binding to Human 
Fibronectin from Plasma and tissue.  
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The last ECM binding assay was also done using coated plates with each recombinant 
protein. At this point we used the ECMs listed in Table 2. Since we observed very little 
binding to the ECM components showed above we decided to change some of the 
conditions to incorporate metals in our reaction buffer since both BB0172 and BB0173 
show in silico a metal binding domain (MIDAS). To this end the HBS buffer containing 
Mg2+, Ca2+, Mn2+ was used. As shown in figure 7, rBB0172T and rBB0173T display a 
much higher adhesion to the ECM components tested in the presence of metals than 
without them (figure 5). The ECM Fibronogen exhibited the highest affinity to each 
recombinant protein, while Aggrecan, Vitronectin, Decorin, Elastin and Fibrinogen 
showed the least affinity. Finally, an integrin binding assay, plates coated with each 
integrin, with incubation steps using the HBS buffer containing Ca2+, Mg2+, Mn2+ no 
binding occurred to either recombinant protein BB0172 and BB0173.  
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FIG. 7. ECM Binding Assay using plates coated with recombinant proteins. Binding 
Assay was done with HBS buffer (containing the metals Ca2+, Mg2+, Mn2+). The 
origin of each one of the ECMs I specified in Table 2. 
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CHAPTER IV 
DISCUSSION 
 
The ability of Borrelia burgdorferi to colonize the mammalian host is dependent on its 
ability to rapidly alter gene expression in response to highly disparate environmental 
signals following transmission from infected ticks. Some of the open reading frames 
(ORFs), up-regulated upon infection, are members of a large family of proteins termed 
MSCRAMMs (microbial surface components recognizing adhesive matrix molecules), 
which facilitate adherence of B. burgdorferi to extra-cellular matrix components of the 
host. By comparative genome analysis, a family of von Willebrand factor A (VWFA) 
domain-containing proteins have been identified in B. burgdorferi (31, 37, 39). These 
chromosomally encoded proteins (BB0172, BB0173, BB0175 and BB0325) could be 
involved in the interactions of B. burgdorferi with the mammalian host (37). The VWFA 
domains present in extracellular matrix (ECM) proteins and on eukaryotic cells are 
involved in cell adhesion and protein-protein interactions (4, 5, 8, 21). Therefore, these 
borrelial proteins with VWFA domains might be involved in the adhesion of B. 
burgdorferi to eukaryotic cells, ECM components or to activated platelets and thus play 
a role in the virulence mechanisms of B. burgdorferi. Our first approach to understand 
the role of the borrelial VWFA containing proteins was to evaluate the adhesion of those 
exposed to the bacterial surface to extracellular matrix components.  
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As stated previously, both BB0172 and BB0173 are membrane proteins by in silico 
analysis. Also, in vitro studies performed in our laboratory showed that each protein has 
a transmembrane domain with the VWFA domain located on the outside of the cell 
(Maria Esteve-Gassent, manuscript in preparation). Consequently, the expression of 
these two proteins as recombinant proteins has proven challenging due to the 
transmembrane domain and signal peptides, located within the first 50 to 90 amino acids, 
inducing toxicity to E. coli. To overcome this toxicity effect, the first 50 amino acids on 
BB0172 and the first 90 amino acids on BB0173 were removed during the cloning 
process. The result of this elimination was the truncated version of BB0172 and BB0173 
and allowed expression of both recombinant proteins in E. coli during the first 2-3 hours 
of induction and at enough concentrations that allowed further experiments possible. 
 
The goal of our study was to purify each of the recombinant proteins in its native form 
for their use in the Binding Assays. Therefore, the first purification was done under 
native conditions with buffers containing 250 mM of imidazole. Both proteins were 
found to be insoluble and were located in the lysate pellet. The next purification attempt 
was done under denaturing conditions with buffers containing 8 M Urea. Both proteins 
were soluble, but still unable to be eluted do to a lack of binding to the Ni beads. A 
mixture of native and denaturing conditions was used for the third trial of purification. 
The buffers for this purification included both 8 M Urea and 300 mM imidazole. The 
300 mM imidazole addition to the denaturing buffer increased the stringency to compete 
both imidazole and our His*tagged proteins to the Ni beads. This change enabled the 
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purification of each recombinant protein at concentrations that were appropriate for 
further studies. 
 
Since both rBB0172T and rBB0173T were purified with 8 M Urea the re-naturing of each 
protein was required. To this end, each of the protein was dialyzed, either for 48 hours at 
4ºC or by three hours at room temperature, changing the buffer each hour, with an 
additional over night dialysis at 4ºC. After dialysis each purified protein was 
concentrated, measured using the BCA Assay kit, and then stored at -80ºC. A 
confirmation of dialysis is shown during thawing of each recombinant protein by the 
lack of crystals that normally form when Urea is at colder temperatures.  
 
Consequently, in this study we were able to rescue the lytic phenotype that these type of 
membrane proteins use to have in surrogate hosts, and were able to express and purify 
both borrelial membrane proteins at enough concentration to re-nature and utilize in 
further binding assays. The first binding assay was done using pre-coated plates of 
Fibronectin, Laminin, Collagen I and IV (BioCoatTM, BD). These ECMs were chosen 
because of their relevance during infection processes and because of their commercial 
availability. In addition, the borrelial protein BBK32 was selected as a control for ECM 
binding assays. BBK32 is a known B. burgdorferi Fibronectin binding protein that has 
been extensively studied in recent years (14, 19, 22, 24, 33-36). Since, little to no 
binding occurred for either rBB0172T or rBB0173T three changes in the approach to the 
binding assays were made. First, the plates were coated with each recombinant protein 
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instead of using the commercially available pre-coated plates. Second, more ECM 
components commercially available were included in the study, as seen in table 2. 
BB0172 and BB0173 have a region within their WVFA domain with high similarity to 
typical integrin metal binding domain (MIDAS) (21). Therefore, the new experiments 
were done in the presence of metal ions (Ca2+, Mg2+, Mn2+) (10) to determine whether or 
not this condition facilitated the binding to any of the ECMs by either recombinant 
proteins (15, 23, 32, 39). Under these conditions, both recombinant proteins were able to 
bind to Human Plasma Fibronectin while no binding was observed towards the other 
ECMs tested, which suggests certain specificity.  
 
The ability of Borrelial rBB0172T and rBB0173T to bind to Fibronectin could explain 
why B. burgdorferi BBK32 knock out mutant strains are still able to bind to Fibronectin 
as observed in different studies (20, 24, 36). It has been shown that B. burgdorferi tends 
to encode for multiple proteins with similar adherence fuction such as BBK32 and RevA 
(7, 9, 14, 16, 36) binding to Fibronectin and DbpA/B to decorin (11, 25, 26, 38). 
Consequently, BB0172 and/or BB0173 could be support system to BBK32 binding to 
Fibronectin. In addition, we have observed that BB0172 is expressed when bacteria 
cultures are shifted from RT/pH7.6 (un-fed tick conditions) to 37ºC /pH6.8 (fed tick 
conditions) and stops its expression when adapted to 37ºC. Consequently, BB0172 could 
be binding to Fibronectin during the initial transmission out of the tick and into the host, 
before BBK32 is expressed in enough levels so as to take over the fibronectin binding. 
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Another plausible explanation for BB0172 and BB0173 binding to Fibronectin could be 
that they are used to bind in different tissues other than the tissues BBK32 target.  
 
Taken together, during this study we were able to purify two borrelial outer membrane 
proteins BB0172 and BB0173. Both proteins are encoded in the chromosome and 
contain a VWFA-domain in the central region of the protein, with metal biding 
capabilities. The presence of metals showed to be a limiting factor that regulated the 
biding of these VWFA-domain containing proteins to ECM components. Currently we 
are investigating which of the metals utilized in this study will be the one turning on and 
off the binding of BB0172 and BB0173 to human plasma fibronectin, and whether or not 
they will also be involved in the binding of the borrelial VWFA-domain containing 
proteins to integrins. Moreover, these two proteins could be part of the adhesin 
collection encoded in B. burgdorferi to bind to different tissues in different stages of the 
transmission from the tick to the mammalian host. Having different adhesins expressing 
at different times during transmission, could be a critical step in the biology of B. 
burgdorferi, since it has to rearrange its gene expression to survive during the transition 
in between two complete different environments, the arthropod tick versus the 
mammalian host. In summary, our study started to elucidate the potential role of VWFA-
domain containing proteins in B. burgdorferi and their relevance during the infection 
process.  
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